Key result
Transfemoral access for TAVR was associated with lower in-hospital/30-day mortality (3.3% vs 4.4%; OR 0.69; 95% CI 0.51-0.94; P=0.02) compared to alternative peripheral access.
Why the study?
Outcomes comparing transfemoral and alternative peripheral access for TAVR remained unclear due to limited sample sizes in prior studies.
Does alternative peripheral access compared to transfemoral access affect early mortality and stroke in patients undergoing TAVR?
Meta-Analysis (n=9,004)
Does alternative peripheral access compared to transfemoral access affect early mortality and stroke in patients undergoing TAVR?
Odds Ratio: 0.69 (95% CI 0.51–0.94)
Absolute Event Rate: 3.3% vs 4.4%
p-value: p=0.02
Alternative peripheral access for TAVR is associated with an additional 1.1% risk of early mortality and 1.6% risk of stroke compared to transfemoral access in propensity-matched studies.
TF preferred over AP access given higher early mortality and stroke; propensity-matched data leave open optimized AP strategies in select anatomies.
Background . Transfemoral (TF) access is the gold standard for transcatheter aortic valve replacement (TAVR). Alternative peripheral (AP) artery access such as the carotid or axillary artery is considered when the feasibility of femoral access is in doubt. The outcomes comparison of these 2 approaches is unclear due to limited sample sizes in prior studies. Our aim is to compare the clinical outcomes of TF‐ and AP‐TAVR by conducting a meta‐analysis of propensity‐matched studies. Methods . The PubMed, EMBASE, and Cochrane Library databases from inception up to and including February 2022 were searched by 3 separate researchers to identify articles reporting propensity‐matched, comparative data on TF vs. AP‐TAVR. Clinical outcomes were extracted from the articles and pooled for analysis. Results . Seven prior studies, including 9,004 patients, were included in our study, with 6,729 in the TF group and 2,275 in the AP group. In all studies, the baseline characteristics of the patients were highly propensity‐matched with the full Newcastle‐Ottawa scale. Meta‐analysis revealed higher in‐hospital/30‐day mortality (3.3% vs. 4.4%; OR 0.69; 95% CI (0.51, 0.94); P = 0.02) as well as the incidence of stroke (1.9% vs. 3.5%; OR 0.60; 95% CI (0.43, 0.84); P = 0.003) for the AP group. There were no significant differences in the incidence of major vascular complications, pacemaker implantation, bleeding, or acute kidney injury. Conclusions . Our meta‐analysis of propensity‐matched studies showed AP‐TAVR contains an additional 1.1% risk of early mortality and an additional 1.6% risk of stroke compared to TF‐TAVR. These risks should be considered when deciding on access.
No takes yet. Share an insight, caveat, or question.
McGrath et al. (2023) conducted a meta-analysis in Transcatheter aortic valve replacement (TAVR) (n=9,004). Transfemoral (TF) access vs. Alternative peripheral (AP) access was evaluated on In-hospital/30-day mortality (OR 0.69, 95% CI 0.51, 0.94, p=0.02). Transfemoral access for TAVR was associated with lower in-hospital/30-day mortality (3.3% vs 4.4%; OR 0.69; 95% CI 0.51-0.94; P=0.02) compared to alternative peripheral access.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: